Findings

What do systematic reviews say?

6 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 7 · 100%High 0 · 0%

Adalimumab weekly vs placebo

Change in DLQI score (LOCF) · participants with hidradenitis suppurativa

2 findings from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
Moderate
Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
Moderate

Adalimumab weekly vs placebo

Frequency of serious adverse effects · participants with hidradenitis suppurativa

Adalimumab weekly showed no clear difference in frequency of serious adverse effects compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
RR 2 [0.38, 10.44]
1 study · 102 participants
Moderate

Adalimumab weekly vs placebo

Treatment discontinuation · participants with hidradenitis suppurativa

Adalimumab weekly showed no clear difference in frequency of treatment discontinuation compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
RR 5 [0.25, 101.63]
1 study · 102 participants
Moderate

Adalimumab weekly vs placebo

Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa

Adalimumab weekly showed no clear difference in proportion of participants with infectious adverse effects compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
RR 0.94 [0.55, 1.62]
1 study · 102 participants
Moderate

Adalimumab weekly vs placebo

Proportion with improvement in pain VAS · participants with hidradenitis suppurativa

Adalimumab weekly probably leads to higher proportion with improvement in pain VAS compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
RR 1.77 [1.02, 3.07]
1 study · 96 participants
Moderate

Adalimumab weekly vs placebo

Change in modified Sartorius scale score (imputation) · participants with hidradenitis suppurativa

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
Moderate